Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Vor Biopharma (NASDAQ:VOR) posted its quarterly earnings data on Thursday. The company reported ($3.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27), Zacks reports.

Vor Biopharma Trading Up 4.4%

Vor Biopharma stock traded up $0.43 during mid-day trading on Friday, reaching $10.18. The company had a trading volume of 436,060 shares, compared to its average volume of 438,619. The stock has a market cap of $69.70 million, a price-to-earnings ratio of -0.04 and a beta of 2.02. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The stock’s 50 day simple moving average is $29.53.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Zacks Research upgraded Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, September 24th. Robert W. Baird raised shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $20.00 to $64.00 in a research note on Wednesday, October 15th. HC Wainwright dropped their price objective on shares of Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a research note on Friday. Finally, Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.17.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 24,579 shares of Vor Biopharma stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $25.12, for a total value of $617,424.48. Following the completion of the sale, the director directly owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. This trade represents a 3.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the completion of the transaction, the insider directly owned 1,167,109 shares in the company, valued at approximately $35,071,625.45. The trade was a 0.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 2,431,718 shares of company stock valued at $62,090,254. 0.45% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vor Biopharma during the 1st quarter valued at $140,000. XTX Topco Ltd bought a new position in Vor Biopharma during the second quarter worth $66,000. BNP Paribas Financial Markets boosted its stake in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after acquiring an additional 5,058 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the third quarter worth $230,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.